All In Biotech

Drug Trial Radar · NCT04580654

A Study to Assess the Pharmacokinetics and Safety of CSL312 in Healthy Japanese and Caucasian Adults

A 2-Part, Phase 1, Single Center, Open-label, Single Ascending Dose Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Subcutaneous and Intravenous CSL312 in Healthy Adult Japanese and Caucasian Subjects

Last checked: Nov 20, 2026Latest source record: Oct 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

38

Actual

Start

Oct 29, 2020

Primary completion

May 7, 2021

Study completion May 7, 2021

Sponsor

Lead sponsor
CSL BehringIndustry
Sponsor type
Industry
First posted
Oct 8, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This will be a 2- part, phase 1, open-label, single center, single ascending dose study to investigate the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of subcutaneous (SC) and intravenous (IV) administration of CSL312 in healthy adult Japanese and Caucasian subjects.

Conditions

  • Healthy Volunteers

Interventions

  • CSL312Biological

    Fully human immunoglobulin G4/lambda recombinant monoclonal antibody against Factor XIIa

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum plasma concentration (Cmax) of CSL312 after subcutaneous dosingTime frame: Up to 85 days postdose
  2. Area under the curve (AUC) from time 0 extrapolated to infinity (AUC0-inf) of CSL312 after subcutaneous dosingTime frame: Up to 85 days postdose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Anaheim Clinical Trials, LLC

    Anaheim, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.